RJA
SPRY icon

Raymond James & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Raymond James & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.97M Buy
+204,783
New +$2.44M ﹤0.01% 1980

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Raymond James & Associates's SPRY Position: Q3 2024 in Review

Raymond James & Associates opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2024: 204,783 shares worth $2.97M. The stake represents ﹤0.01% of the portfolio and ranks #1980 among its holdings.

150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Raymond James & Associates held 204,783 shares of ARS Pharmaceuticals worth $2.97M as of Q3 2024.
  • ARS Pharmaceuticals was a new Raymond James & Associates position in Q3 2024.
  • ARS Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1980 holding.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.